The emergence of RECEPTA biopharma is the realization of competitive advantages that Brazil offers for R&D activities in biotechnology related to the area of human health. The following elements of viability can be highlighted:
a) Highly qualified scientific and technologically savvy human resources for the implementation of R&D activities; these personnel are currently under utilized by the country's innovation system.
b) Scientific and technological Centers of Excellence that make possible a strategy of outsourcing R&D activities by way of partnerships.
c) Highly qualified and experienced hospital and medical centers for the conduct of clinical trials.
d) Access to patients for participation in clinical trials and tumor tissue for in vitro analyses.
e) Significantly lower costs than in the developed countries.
d) Insertion of the Company's activity in sectors defined as priorities by the Industrial, Technological and Foreign Commerce Policy (PITCE): the development of medicines and biotechnology, an area classified as "the door to the future" by the PITCE. The strategic relevance of the Company's project for the country exclusively qualifies RECEPTA biopharma to obtain support in programs directed towards advancing technological innovation.